Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have received a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $46.67.

Several equities analysts have recently weighed in on NBTX shares. Leerink Partners boosted their target price on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Finally, Guggenheim assumed coverage on shares of Nanobiotix in a research report on Tuesday, September 15th. They set a “buy” rating and a $64.00 price objective on the stock.

Nanobiotix Price Performance

Shares of NASDAQ:NBTX opened at $33.31 on Monday. Nanobiotix has a 12 month low of $14.78 and a 12 month high of $57.14. The company has a 50-day moving average price of $38.73 and a 200 day moving average price of $37.34.

Nanobiotix (NASDAQ:NBTX) last issued its quarterly earnings data on Tuesday, September 29th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.08. The company had revenue of $3.17 million for the quarter, compared to the consensus estimate of $1.73 million. Research analysts expect that Nanobiotix will post -0.16 earnings per share for the current fiscal year.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.